TrialLancet (London, England)2012

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.

Paul M Ridker et al.PubMed ↗Full text ↗Publisher ↗

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with fewer deaths

−52%−67% to −32%

Bigger than 9 in 10 for all-cause mortality

As reported

HR 0.48, 95% CI 0.33–0.68 · the paper's word: All-cause mortality

Correlation, not cause

Went with fewer deaths

−39%−53% to −21%

Bigger than 9 in 10 for all-cause mortality

As reported

HR 0.61, 95% CI 0.47–0.79 · the paper's word: All-cause mortality

Two numbers in the abstract

the abstract, start to end

… reduction in the primary endpoint (HR 0.48, 95% CI 0.33-0.68, p=0.0001), a …

… the primary endpoint (hazard ratio [HR] 0.61, 95% CI 0.47-0.79, p=0.0001), a …

← favours treatmentfavours comparator →

could be chance

All-cause mortality

HR 0.480.33–0.68

All-cause mortality

HR 0.610.47–0.79

StatinsAll-cause mortality

1 / 3

311 papers cite itlatest 60 shown

2012

…

2017

2018

2019

2021

2022

2023

2024

2025

2026

this paperpooled ittrialcites it

9 trials

NCT02255682phase 435 enrolled2015 NCT02437084phase 4115 enrolled2015 NCT02740699phase 479 enrolled2016 NCT02796378phase 430 enrolled2016 NCT00239681phase 317,802 enrolled2003 NCT0225067775 enrolled2014

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.

What moved togetherboth groups pooled, not the treatment’s effect

Went with fewer deaths

Went with fewer deaths

Two numbers in the abstract

Where each one falls

Where it lands on the map

311 papers cite itlatest 60 shown

9 trials